This encompasses thetreatment of preoperative anemia or coagulopathies (first pillar); bleeding/bloodloss minimization during the IO/PO periods (second pillar); and changes in themedical concept of anemia beyond hemoglobin (Hb) or hematocrit (Ht) parameters andstrengthening the patient's own physiological reserves, especially in the PO period(third pillar)[8-10]. The gene discussed is GSTM1; the disease is anemia.